Bauersachs J, Thum T, Frantz S, Ertl G
Eur J Clin Invest. 2005 Jul;35(7):417-20. doi: 10.1111/j.1365-2362.2005.01510.x.
Recent experimental and clinical trials give rise to the hope that progenitor cells could replace scar tissue after myocardial infarction with healthy functional myocardium. However, while a significant increase in left ventricular ejection fraction has been described after progenitor cell transplantation in several clinical trials, long-term results are lacking, and the mechanisms underlying the improvement of ejection fraction are unclear. Therefore, the efficacy of progenitor cell transplantation after myocardial infarction has not been established, and potential problems may have been underestimated. In-depth laboratory and animal studies are needed to determine the best cell type, optimal amount of cells, and time point for transplantation. Treatment of patients with progenitor cells outside well controlled prospective trials should be avoided.
近期的实验和临床试验带来了这样的希望，即祖细胞可以用健康的功能性心肌替代心肌梗死后的瘢痕组织。然而，虽然在一些临床试验中描述了祖细胞移植后左心室射血分数有显著增加，但缺乏长期结果，且射血分数改善的潜在机制尚不清楚。因此，心肌梗死后祖细胞移植的疗效尚未确立，潜在问题可能也被低估了。需要深入的实验室和动物研究来确定最佳的细胞类型、最佳的细胞数量以及移植的时间点。应避免在严格控制的前瞻性试验之外用祖细胞治疗患者。
